Figure 7
DETT delays myeloma tumour growth in nude mice models. Three million of RPMI-8226 cells were subcutaneously injected in the right flank of each mouse. When tumours were palpable, mice were randomly distributed into two groups, one was orally given DETT (50 mg kg−1) every day, while the other was received the same volume of vehicle. Mice weight and tumour sizes were monitored every other day. (A) The curves of tumour sizes (*, P=0.000444). (B) Tumour weight was measured at the end of the experiment after tumours were excised. (C) The body weights were not markedly changed by DETT based on a measurement every other day. (D) DETT suppressed the expression of p65, phospho-p65, and p50 and cleaved PARP in the tumour tissues from DETT-treated mice.
